You have full text access to this OnlineOpen article

Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro

  1. Pedro D'Orléans-Juste*,
  2. Sabine Télémaque,
  3. Audrey Claing

Article first published online: 19 JUL 2012

DOI: 10.1111/j.1476-5381.1991.tb12448.x

Issue

British Journal of Pharmacology

British Journal of Pharmacology

Volume 104, Issue 2, pages 440–444, October 1991

Additional Information

How to Cite

D'Orléans-Juste, P., Télémaque, S. and Claing, A. (1991), Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro. British Journal of Pharmacology, 104: 440–444. doi: 10.1111/j.1476-5381.1991.tb12448.x

Author Information

  1. Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada

* Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada

Publication History

  1. Issue published online: 19 JUL 2012
  2. Article first published online: 19 JUL 2012
  3. Received April 12, 1991; Revised June 1, 1991; Accepted June 10, 1991

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (994K)

References

  • BAKHLE, Y.S., REYNARD, A.M. & VANE, J.R. (1969). Metabolism of the angiotensins in isolated perfused tissues. Nature, 222, 956–959.
  • BLOCH, K.D., EDDY, R.L., SHOWS, T.B. & QUERTERMOUS, T. (1989). cDNA cloning and chromosomal assignment of the gene encoding endothelin-3. J. Biol. Chem., 264, 18156–18161.
  • DE NUCCI, G., THOMAS, R., D'ORLÉANS-JUSTE, P., ANTUNES, E., WALDER, C., WARNER, T. & VANE, J.R. (1988). Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U.S.A., 85, 9797–9800.
  • D'ORLÉANS-JUSTE, P., LIDBURY, P.S., CAPPER, S.J., WARNER, T.D. & VANE, J.R. (1990a). Exogenous human big-endothelin is converted to endothelin-1 in the rabbit in vivo. Br. J. Pharmacol., 101, 510P.
  • D'ORLÉANS-JUSTE, P., LIDBURY, P.S., WARNER, T.D. & VANE, J.R. (1990b). Intravascular big-endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochem. Pharmacol., 39, R21–R22.
  • D'ORLÉANS-JUSTE, P., LIDBURY, P.S., TÉLÉMAQUE, S., WARNER, T.D. & VANE, J.R. (1991). Human big-endothelin releases prostacyclin in vivo and also in vitro through a phosphoramidon-sensitive conversion to endothelin-1. J. Cardiovasc. Pharmacol., (in press).
  • EMORI, T., HIRATA, Y. & MARUMO, F. (1990). Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett., 263, 261–264.
  • FUKURODA, F., NOGUCHI, K., TSUCHIDA, S., NISHIKIBE, M., IKEMOTO, F., OKADA, K. & YANO, M. (1990). Inhibition of biological actions of big-endothelin-1 by phosphoramidon. Biochem. Biophys. Res. Commun., 172, 390–395.
  • GRANSTRÖM, E., KINDAHL, H. & SAMUELSON, B. (1976). Radioimmunoassay for thromboxane B2. Anal. Lett., 9, 611–627.
  • INOUE, A., YANAGISAWA, M., KIMURA, S., KASUYA, Y., MIYAUCHI, T., GOTO, K. & MASAKI, T. (1989). The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A., 86, 2863–2867.
  • KASHIWABARA, T., INAGAKI, Y., OHTA, H., IWAMATSU, A., NOMIZU, M., MORITA, A. & NISHIKORI, K. (1989). Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett., 247, 73–76.
  • MATSUMOTO, H., SUZUKI, N., ONDA, H. & FUJINO, M. (1989). Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem. Biophys. Res. Commun., 164, 74–80.
  • MATSUMURA, Y., HISAKI, K., TAKAOKA, M. & MORIMOTO, S. (1990). Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big-endothelin-1. Eur. J. Pharmacol., 185, 103–106.
  • McMAHON, E.G., FOK, K.F., MOORE, W.M., SMITH, C.E., SIEGEL, N.R. & TRAPANI, A.J. (1989). In vitro and in vivo activity of chymotrypsin-activated big-endothelin (porcine 1–40). Biochem. Biophys. Res. Commun., 161, 406–413.
  • McMAHON, E.G., PALOMO, M.A., MOORE, W.M., McDONALD, J.F. & STERN, M.K. (1991). Phosphoramidon blocks the pressor activity of porcine big-endothelin-1 (1–39) in vivo and conversion of big-endothelin-1 (1–39) to endothelin (1–21) in vitro. Proc. Natl. Acad. Sci. U.S.A., 88, 703–707.
  • MUMFORD, R.A., PIERZCHALA, P.A., STRAUSS, A.W. & ZIMMERMAN, M. (1981). Purification of a membrane-bound metalloendopeptidase from porcine kidney that degrades peptide hormones. Proc. Natl. Acad. Sci. U.S.A., 78, 6623–6627.
  • OKADA, K., MIYASAKI, Y., TAKADA, J., MATSUYAMA, K., YAMAKI, T. & YANO, M. (1990). Conversion of big-endothelin-1 by membrane-bound metalloendopeptidase in cultured bovine endothelial cells. Biochem. Biophys. Res. Commun., 171, 1192–1198.
  • PONS, F., LOQUET, I., TOUVAY, C., ROUBERT, P., CHABRIER, P.-E., MENCIA-HUERTA, J.M. & BRAQUET, P. (1991). Comparison of the bronchopulmonary and pressor activities of endothelin isoforms ET-1, ET-2 and ET-3 and characterization of their binding sites in guinea-pig lung. Am. Rev. Resp. Dis., 143, 294–300.
  • ROUISSI, N., NANTEL, F., DRAPEAU, G., RHALEB, N.E., DION, S. & REGOLI, D. (1990). Inhibitors of peptidases: how they influence the biological activities of substance P, neurokinins, kinins and angiotensins in the guinea pig, hamster and rat urinary bladders. Pharmacology, 40, 186–204.
  • SALMON, J.A. (1978). A radioimmunoassay for 6-keto-prostaglandin F1α. Prostaglandins, 15, 383–397.
  • SUDA, H., AOYAGI, T., TAKEUCHI, T.E. & UMEZAWA, H. (1973). Letter: a thermolysin inhibitor produced by actinomycetes, phosphoramidon. J. Antiobiot., 26, 621–623.
  • WALLACE, J.L., KEENAN, C.M., MACNAUGHTON, W.K. & McKNIGHT, G.W. (1989). Comparison of the effects of endothelin-1 and endothelin-3 on the rat stomach. Eur. J. Pharmacol., 167, 41–47.
  • WHITTLE, B.J.R., PAYNE, A. & ESPLUGUES, J.V. (1989). Cardiopulmonary and gastric ulcerogenic actions of endothelin-1 in the guinea-pig and rat. J. Cardiovasc. Pharmacol., 13, S103–S107.
  • YAMAJI, T., JOHSHITA, H., ISHIBASHI, M., TAKAKU, F., OHNO, H., SUZUKI, N., MATSUMOTO, H. & FUJINO, M. (1990). Endothelin family in human plasma and cerebrospinal fluid. J. Clin. Endocrinol. Metab., 71, 1611–1615.
  • YANAGISAWA, M., KURIHARA, S., KIMURA, Y., TOMOBE, Y., KOBAYASHI, M., MITSUI, Y., YASAKI, Y., GOTO, K. & MASAKI, T. (1988a). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411–415.
  • YANAGISAWA, M., INOUE, A., ISHIGAWA, T., KASUYA, Y., KIMURA, S., KUMAGAYE, S., NAKAJIMA, K., WATANABE, T.X., SAKAKIBARA, S., GOTO, K. & MASAKI, T. (1988b). Primary structure, synthesis and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc. Natl. Acad. Sci. U.S.A., 85, 6964–6967.
Get PDF (994K)